Biomark Diagnostics Inc. develops early-stage cancer diagnostic technology platform to detect and treat cancer. The company invests in and develops a liquid biopsy metabolic panel assay for the early-stage diagnosis of lung cancer and glioblastoma (GBM) breast cancer. It is also developing liquid biopsy tests for various cancer types, including glioblastoma, gastrointestinal, prostate, head, neck cancers. The company was incorporated in 2014 and is headquartered in Richmond, Canada.
Research context
Biomark Diagnostics Inc appears in PyInvesting’s Frankfurt Stock catalogue. The price history above describes this recorded instrument; it does not by itself identify a company’s business or establish a continuous investment return.
- Currency
- EUR
- Sector
- Healthcare
- Industry
- Diagnostics & Research
These are the latest stored catalogue classifications, not a historical classification snapshot. An issuer description, classification effective date or currency may be unavailable. Check the issuer’s own disclosures and the observation dates before using these fields for research.
Review backtest assumptions and evidence before treating a chart or stored history as a research result.
5 years, 6 months ago
Biomark Diagnostics Inc is currently in a long term downtrend where the price is trading 12.9% below its 200 day moving average.
From a valuation standpoint, the stock is 93.1% cheaper than other stocks from the Healthcare sector with a price to sales ratio of 90.1.
Biomark Diagnostics Inc's total revenue sank by 100.0% to $0 since the same quarter in the previous year.
Its net income has increased by 71.1% to $-194K since the same quarter in the previous year.
Finally, its free cash flow fell by 165.0% to $-229K since the same quarter in the previous year.
Based on the above factors, Biomark Diagnostics Inc gets an overall score of 2/5.